PMID- 33840516
OWN - NLM
STAT- MEDLINE
DCOM- 20211124
LR  - 20211124
IS  - 1879-114X (Electronic)
IS  - 0149-2918 (Linking)
VI  - 43
IP  - 5
DP  - 2021 May
TI  - Association Between the CYP2C9 Genotype and Hypoglycemia Among Patients With Type 
      2 Diabetes Receiving Sulfonylurea Treatment: A Meta-analysis.
PG  - 836-843.e4
LID - S0149-2918(21)00120-X [pii]
LID - 10.1016/j.clinthera.2021.03.008 [doi]
AB  - PURPOSE: Two common variants, CYP2C9*2 (Arg144Cys, rs1799853) and CYP2C9*3 
      (Ile359Leu, rs1057910), are known to reduce the catalytic function of the CYP2C9 
      enzyme. Because impaired catalytic function is likely to affect sulfonylurea 
      metabolism, it is predictable that CYP2C9 loss-of-function alleles may increase 
      the risk of sulfonylurea-induced hypoglycemia. This systematic review and 
      meta-analysis aimed to assess the association between CYP2C9 genotype and 
      hypoglycemia among patients with type 2 diabetes mellitus (T2DM) receiving 
      sulfonylurea. METHODS: We searched for studies on the association between CYP2C9 
      genotype and sulfonylurea-induced hypoglycemia among patients with T2DM, 
      published through August 7, 2020, using PubMed, Web of Science, and EMBASE. Odds 
      ratios (ORs) and 95% CIs were calculated. FINDINGS: Five cohort studies and 2 
      case-control studies were included, and the total number of patients analyzed in 
      this meta-analysis was 2769. The CYP2C9 variant alleles were associated with an 
      increase in sulfonylurea-induced hypoglycemia compared with wild-type homozygote 
      (OR = 1.24; 95% CI, 1.03-1.48). Compared with CYP2C9 wild-type homozygotes, 
      CYP2C9*2 allele was associated with increased incidence of hypoglycemia 
      (OR = 1.85; 95% CI, 1.18-2.89), whereas the CYP2C9*3 allele failed to show the 
      statistical significance (OR = 1.67; 95% CI, 0.40-6.86; P = 0.48). IMPLICATIONS: 
      On the basis of these results, CYP2C9 genotyping may be useful for predicting the 
      risk of hypoglycemia during sulfonylurea treatment for T2DM.
CI  - Copyright (c) 2021 Elsevier Inc. All rights reserved.
FAU - Yee, Jeong
AU  - Yee J
AD  - College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans 
      University, Seoul, Republic of Korea.
FAU - Heo, Yunhee
AU  - Heo Y
AD  - College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans 
      University, Seoul, Republic of Korea.
FAU - Kim, Hamin
AU  - Kim H
AD  - College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans 
      University, Seoul, Republic of Korea.
FAU - Yoon, Ha Young
AU  - Yoon HY
AD  - College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans 
      University, Seoul, Republic of Korea.
FAU - Song, Gonjin
AU  - Song G
AD  - College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans 
      University, Seoul, Republic of Korea.
FAU - Gwak, Hye Sun
AU  - Gwak HS
AD  - College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans 
      University, Seoul, Republic of Korea. Electronic address: hsgwak@ewha.ac.kr.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20210408
PL  - United States
TA  - Clin Ther
JT  - Clinical therapeutics
JID - 7706726
RN  - 0 (Sulfonylurea Compounds)
RN  - EC 1.14.13.- (CYP2C9 protein, human)
RN  - EC 1.14.13.- (Cytochrome P-450 CYP2C9)
SB  - IM
MH  - Alleles
MH  - Cytochrome P-450 CYP2C9/genetics
MH  - *Diabetes Mellitus, Type 2/drug therapy/genetics
MH  - Genotype
MH  - Humans
MH  - *Hypoglycemia/chemically induced/genetics
MH  - Sulfonylurea Compounds/adverse effects
OTO - NOTNLM
OT  - CYP2C9
OT  - hypoglycemia
OT  - polymorphism
OT  - sulfonylurea
OT  - type 2 diabetes
COIS- Disclosures The authors have indicated that they have no other conflicts of 
      interest regarding the content of this article.
EDAT- 2021/04/13 06:00
MHDA- 2021/11/25 06:00
CRDT- 2021/04/12 05:35
PHST- 2020/12/30 00:00 [received]
PHST- 2021/02/25 00:00 [revised]
PHST- 2021/03/12 00:00 [accepted]
PHST- 2021/04/13 06:00 [pubmed]
PHST- 2021/11/25 06:00 [medline]
PHST- 2021/04/12 05:35 [entrez]
AID - S0149-2918(21)00120-X [pii]
AID - 10.1016/j.clinthera.2021.03.008 [doi]
PST - ppublish
SO  - Clin Ther. 2021 May;43(5):836-843.e4. doi: 10.1016/j.clinthera.2021.03.008. Epub 
      2021 Apr 8.